|
gptkbp:instanceOf
|
gptkb:drug
sedative
nonbenzodiazepine
|
|
gptkbp:approvalYear
|
2004
|
|
gptkbp:approvedBy
|
gptkb:United_States
gptkb:FDA
|
|
gptkbp:ATCCode
|
N05CF04
|
|
gptkbp:brand
|
gptkb:Lunesta
|
|
gptkbp:CASNumber
|
138729-47-2
|
|
gptkbp:cause
|
withdrawal symptoms
complex sleep behaviors
next-day impairment
|
|
gptkbp:chemicalFormula
|
C17H17ClN6O3
|
|
gptkbp:compatibleWith
|
gptkb:European_Union
|
|
gptkbp:contraindication
|
severe liver impairment
hypersensitivity to eszopiclone
|
|
gptkbp:controlledSubstanceSchedule
|
Schedule IV (US)
|
|
gptkbp:developedBy
|
gptkb:Sepracor
|
|
gptkbp:drugClass
|
cyclopyrrolone
|
|
gptkbp:eliminationHalfLife
|
6 hours
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Eszopiclone
|
|
gptkbp:interactsWith
|
gptkb:beer
CYP3A4 inhibitors
CYP3A4 inducers
other CNS depressants
|
|
gptkbp:IUPACName
|
(5S)-6-(5-chloro-2-pyridyl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate
|
|
gptkbp:KEGGID
|
D04022
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
GABA-A receptor agonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
388.81 g/mol
|
|
gptkbp:overdoseSymptoms
|
coma
respiratory depression
excessive sedation
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201197
837211
969434
|
|
gptkbp:relatedTo
|
gptkb:zopiclone
|
|
gptkbp:riskOfDependence
|
yes
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
headache
drowsiness
dry mouth
memory impairment
unpleasant taste
|
|
gptkbp:UNII
|
U5A474A1B3
|
|
gptkbp:usedFor
|
treatment of insomnia
|
|
gptkbp:bfsParent
|
gptkb:Nonbenzodiazepine_hypnotics
|
|
gptkbp:bfsLayer
|
6
|